U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C20H27N5O2
Molecular Weight 369.4607
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CILOSTAZOL

SMILES

O=C1CCC2=CC(OCCCCC3=NN=NN3C4CCCCC4)=CC=C2N1

InChI

InChIKey=RRGUKTPIGVIEKM-UHFFFAOYSA-N
InChI=1S/C20H27N5O2/c26-20-12-9-15-14-17(10-11-18(15)21-20)27-13-5-4-8-19-22-23-24-25(19)16-6-2-1-3-7-16/h10-11,14,16H,1-9,12-13H2,(H,21,26)

HIDE SMILES / InChI

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/11830753

Cilostazol is a PDE3 inhibitor which is used for the treatment of intermittent claudication. The drug positively affects the platelet aggregation and may be used off-label as a measure to prevent coronary thrombosis/restenosis and stroke recurrence.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
0.57 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
CILOSTAZOL

Approved Use

Cilostazol tablets are indicated for the reduction of symptoms of intermittent claudication, as indicated by an increased walking distance.

Launch Date

2004
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
701 ng/mL
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CILOSTAZOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
9.2 ng/mL
0.5 mg/kg single, oral
dose: 0.5 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
CILOSTAZOL serum
Rattus norvegicus
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
13724 ng × h/mL
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CILOSTAZOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
17.5 ng × h/mL
0.5 mg/kg single, oral
dose: 0.5 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
CILOSTAZOL serum
Rattus norvegicus
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
13.5 h
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CILOSTAZOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
58.7%
0.5 mg/kg single, oral
dose: 0.5 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
CILOSTAZOL serum
Rattus norvegicus
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
3.5%
CILOSTAZOL plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
PubMed

PubMed

TitleDatePubMed
Potent effects of novel anti-platelet aggregatory cilostamide analogues on recombinant cyclic nucleotide phosphodiesterase isozyme activity.
2000 Feb 15
Peripheral arterial disease.
2001
Effect of cilostazol on endothelial cell denudation and proliferation in canine vein grafts.
2001
Estimation of anti-platelet drugs on human platelet aggregation with a novel whole blood aggregometer by a screen filtration pressure method.
2001 Aug
Cilostazol: treatment of intermittent claudication.
2001 Jan
Effects of cilostazol on late lumen loss and repeat revascularization after Palmaz-Schatz coronary stent implantation.
2001 Jan
Cilostazol suppresses intimal formation in dog grafted veins with reduction of angiotensin II-forming enzymes.
2001 Jan 12
The effect of cilostazol on glucose tolerance and insulin resistance in a rat model of non-insulin dependent diabetes mellitus.
2001 Jun
Comparative effects of cilostazol and other therapies for intermittent claudication.
2001 Jun 28
Intermittent claudication: effective medical management of a common circulatory problem.
2001 Jun 28
Intermittent claudication: magnitude of the problem, patient evaluation, and therapeutic strategies.
2001 Jun 28
Effect of cilostazol on restenosis after coronary angioplasty and stenting in comparison to conventional coronary artery stenting with ticlopidine.
2001 May
Pharmacotherapy of intermittent claudication.
2001 Nov
Systemic atherosclerosis risk and the mandate for intervention in atherosclerotic peripheral arterial disease.
2001 Oct 11
Differential effects of cilostazol and pentoxifylline on vascular endothelial growth factor in patients with intermittent claudication.
2001 Sep
Cilostazol treatment of claudication in diabetic patients.
2002
Randomized comparison of cilostazol versus ticlopidine hydrochloride for antiplatelet therapy after coronary stent implantation for prevention of late restenosis.
2002 Aug
Polymorphic forms of cilostazol.
2002 Aug
Can claudication be improved with medication?
2002 Dec
Spontaneous recanalization of arterial occlusions: an unusual mechanism for symptomatic improvement.
2002 Dec
Thermally-prepared polymorphic forms of cilostazol.
2002 Dec
Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication.
2002 Dec 15
Inhibition of lipopolysaccharide-induced apoptosis by cilostazol in human umbilical vein endothelial cells.
2002 Feb
Current medical therapies for patients with peripheral arterial disease: a critical review.
2002 Jan
Potential emerging therapeutic strategies to prevent restenosis in the peripheral vasculature.
2002 Jul
Peripheral arterial disease.
2002 Jun
[Antiproliferative coated stents and intracoronary brachytherapy: common traits and differences].
2002 Jun
Recent advances in antiplatelet agents.
2002 Mar
Effects of cilostazol, a selective cyclic AMP phosphodiesterase inhibitor on isolated rabbit spinal arterioles.
2002 Oct
Debulking and stenting versus debulking only of coronary artery disease in patients treated with cilostazol (final results of ESPRIT).
2002 Sep 15
Effects of cilostazol on serum lipid concentrations and plasma fatty acid composition in type 2 diabetic patients with peripheral vascular disease.
2003 Feb
Patents

Sample Use Guides

The recommended dosage of cilostazol tablets is 100 mg b.i.d. taken at least half an hour before or 2 hours after breakfast and dinner.
Route of Administration: Oral
In vitro assay of anti-platelet effects of cilostazol against collagen-induced aggregation using Multiplate produced a graded dose-dependent inhibition curve with IC50 value of 75.4 ± 2.4 uM while it showed a highly sensitive and all-or-none type inhibition response from 25 uM in PFA-100.
Name Type Language
CILOSTAZOL
INN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
USAN   INN  
Official Name English
6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril
Common Name English
CILOSTAZOL [MI]
Common Name English
OPC-21
Code English
2(1H)-QUINOLINONE, 6-(4-(1-CYCLOHEXYL-1H-TETRAZOL-5-YL)BUTOXY)-3,4-DIHYDRO-
Systematic Name English
CILOSTAZOL [USP-RS]
Common Name English
NSC-758936
Code English
CILOSTAZOL [JAN]
Common Name English
Cilostazol [WHO-DD]
Common Name English
OPC-13013
Code English
CILOSTAZOL [VANDF]
Common Name English
CILOSTAZOL [USAN]
Common Name English
PLETAL
Brand Name English
CILOSTAZOL [MART.]
Common Name English
CILOSTAZOL [USP MONOGRAPH]
Common Name English
cilostazol [INN]
Common Name English
CILOSTAZOL [ORANGE BOOK]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C744
Created by admin on Fri Dec 15 15:38:29 GMT 2023 , Edited by admin on Fri Dec 15 15:38:29 GMT 2023
NCI_THESAURUS C1327
Created by admin on Fri Dec 15 15:38:29 GMT 2023 , Edited by admin on Fri Dec 15 15:38:29 GMT 2023
WHO-ATC B01AC23
Created by admin on Fri Dec 15 15:38:29 GMT 2023 , Edited by admin on Fri Dec 15 15:38:29 GMT 2023
LIVERTOX NBK547957
Created by admin on Fri Dec 15 15:38:29 GMT 2023 , Edited by admin on Fri Dec 15 15:38:29 GMT 2023
WHO-VATC QB01AC23
Created by admin on Fri Dec 15 15:38:29 GMT 2023 , Edited by admin on Fri Dec 15 15:38:29 GMT 2023
NDF-RT N0000175598
Created by admin on Fri Dec 15 15:38:29 GMT 2023 , Edited by admin on Fri Dec 15 15:38:29 GMT 2023
NDF-RT N0000175086
Created by admin on Fri Dec 15 15:38:29 GMT 2023 , Edited by admin on Fri Dec 15 15:38:29 GMT 2023
Code System Code Type Description
MESH
C045645
Created by admin on Fri Dec 15 15:38:29 GMT 2023 , Edited by admin on Fri Dec 15 15:38:29 GMT 2023
PRIMARY
CAS
73963-72-1
Created by admin on Fri Dec 15 15:38:29 GMT 2023 , Edited by admin on Fri Dec 15 15:38:29 GMT 2023
PRIMARY
NCI_THESAURUS
C1051
Created by admin on Fri Dec 15 15:38:29 GMT 2023 , Edited by admin on Fri Dec 15 15:38:29 GMT 2023
PRIMARY
CHEBI
31401
Created by admin on Fri Dec 15 15:38:29 GMT 2023 , Edited by admin on Fri Dec 15 15:38:29 GMT 2023
PRIMARY
FDA UNII
N7Z035406B
Created by admin on Fri Dec 15 15:38:29 GMT 2023 , Edited by admin on Fri Dec 15 15:38:29 GMT 2023
PRIMARY
IUPHAR
7148
Created by admin on Fri Dec 15 15:38:29 GMT 2023 , Edited by admin on Fri Dec 15 15:38:29 GMT 2023
PRIMARY
MERCK INDEX
m3550
Created by admin on Fri Dec 15 15:38:29 GMT 2023 , Edited by admin on Fri Dec 15 15:38:29 GMT 2023
PRIMARY Merck Index
SMS_ID
100000081054
Created by admin on Fri Dec 15 15:38:29 GMT 2023 , Edited by admin on Fri Dec 15 15:38:29 GMT 2023
PRIMARY
PUBCHEM
2754
Created by admin on Fri Dec 15 15:38:29 GMT 2023 , Edited by admin on Fri Dec 15 15:38:29 GMT 2023
PRIMARY
DRUG BANK
DB01166
Created by admin on Fri Dec 15 15:38:29 GMT 2023 , Edited by admin on Fri Dec 15 15:38:29 GMT 2023
PRIMARY
WIKIPEDIA
CILOSTAZOL
Created by admin on Fri Dec 15 15:38:29 GMT 2023 , Edited by admin on Fri Dec 15 15:38:29 GMT 2023
PRIMARY
NSC
758936
Created by admin on Fri Dec 15 15:38:29 GMT 2023 , Edited by admin on Fri Dec 15 15:38:29 GMT 2023
PRIMARY
DRUG CENTRAL
644
Created by admin on Fri Dec 15 15:38:29 GMT 2023 , Edited by admin on Fri Dec 15 15:38:29 GMT 2023
PRIMARY
LACTMED
Cilostazol
Created by admin on Fri Dec 15 15:38:29 GMT 2023 , Edited by admin on Fri Dec 15 15:38:29 GMT 2023
PRIMARY
HSDB
8312
Created by admin on Fri Dec 15 15:38:29 GMT 2023 , Edited by admin on Fri Dec 15 15:38:29 GMT 2023
PRIMARY
RS_ITEM_NUM
1134153
Created by admin on Fri Dec 15 15:38:29 GMT 2023 , Edited by admin on Fri Dec 15 15:38:29 GMT 2023
PRIMARY
USAN
II-72
Created by admin on Fri Dec 15 15:38:29 GMT 2023 , Edited by admin on Fri Dec 15 15:38:29 GMT 2023
PRIMARY
EVMPD
SUB06273MIG
Created by admin on Fri Dec 15 15:38:29 GMT 2023 , Edited by admin on Fri Dec 15 15:38:29 GMT 2023
PRIMARY
RXCUI
21107
Created by admin on Fri Dec 15 15:38:29 GMT 2023 , Edited by admin on Fri Dec 15 15:38:29 GMT 2023
PRIMARY RxNorm
EPA CompTox
DTXSID9045132
Created by admin on Fri Dec 15 15:38:29 GMT 2023 , Edited by admin on Fri Dec 15 15:38:29 GMT 2023
PRIMARY
INN
5680
Created by admin on Fri Dec 15 15:38:29 GMT 2023 , Edited by admin on Fri Dec 15 15:38:29 GMT 2023
PRIMARY
DAILYMED
N7Z035406B
Created by admin on Fri Dec 15 15:38:29 GMT 2023 , Edited by admin on Fri Dec 15 15:38:29 GMT 2023
PRIMARY
ChEMBL
CHEMBL799
Created by admin on Fri Dec 15 15:38:29 GMT 2023 , Edited by admin on Fri Dec 15 15:38:29 GMT 2023
PRIMARY